Supported by educational grants from Astellas and Medivation, Inc. a Pfizer company, AstraZeneca, and Genomic Health.
Non-metastatic castrate resistant prostate cancer RPC (nmCRPC) is defined as a clinical state where patients, despite achieving castrate levels of testosterone with androgen deprivation therapy (ADT), exhibit progressive disease as determined by biochemical evidence of recurrence (ie, rising prostate-specific antigen [PSA] levels), with no evidence of radiographic metastases. As a newly defined disease state associated with a degree of clinical uncertainty, many clinicians face challenges managing patients with nmCRPC in practice. This is particularly true in light of growing “PSA anxiety” experienced among patients who worry as their PSA levels rise and want to know what their treatment options are. Challengingly, this nmCRPC population is clinically heterogeneous, with patients presenting with varying degrees of disease aggressiveness and prognosis. Recently completed and ongoing studies have established the role of antiandrogen receptor agents for treatment of patients with nmCRPC, with 1 agent recently receiving US Food and Drug Administration approval as the first, and currently only, treatment for patients with this indication. Despite promising results with these agents, many questions remain regarding their appropriate use in patients with nmCRPC. This Expert Panel discussion among 3 oncology specialists will review our current understanding of nmCRPC, the current clinical data for anti-AR therapies for patients with nmCRPC, how to identify appropriate patients, managing associated toxicities, the effect on subsequent therapy options, and expected outcomes.
The goal of this program is for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer to obtain the necessary information to effectively use anti-AR therapy in appropriate nmCRPC patients.
This educational initiative is intended for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer. No prerequisites required.
After completing this activity, participants will demonstrate the ability to:
Accredidation Statement
In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA), to provide continuing education for the healthcare team.
Credit Designation Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 interprofessional Continuing Education (IPCE) credits for learning and change.
The estimated time to complete this activity: 30 minutes.
Release date: October 10, 2018. Expiration date: October 10, 2019.
COURSE DIRECTOR
George K. Philips, MBBS, MD, MPH
Genitourinary Oncology
MedStar Georgetown University Hospital
MedStar Washington Hospital Center
Georgetown Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC
PARTICIPATING FACULTY
Jeanny Aragon-Ching, MD
GU Medical Oncology
Inova Schar Cancer Institute
Department of Medicine
Virginia Commonwealth University
Fairfax, Virginia
Ross E. Krasnow, MD, MPH
MedStar Washington Hospital Center
Washington, DC
DISCLOSURES
No faculty members have indicated that they have any financial interests or relationships with a commercial entity.
ACTIVITY
Instructions
The following is an enduring expert panel discussion activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the archive activity, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity.
Table of Contents
Preassessment
Moving Towards Treating Nonmetastatic CRPC:
Analyzing the Emerging Role of Antiandrogen Therapies – Expert Panel Discussion
George K. Philips, MBBS, MD, MPH, Jeanny Aragon-Ching, MD, and Ross E. Krasnow, MD, MPH
Postassessment and Evaluation
